نتایج جستجو برای: ژن her2

تعداد نتایج: 30284  

2017
Qing-Yun Chong Ming-Liang You Vijay Pandey Arindam Banerjee Yi-Jun Chen Han-Ming Poh Mengyi Zhang Lan Ma Tao Zhu Salundi Basappa Liang Liu Peter E. Lobie

HER2+/ER+ breast cancer, a subset of the luminal B subtype, makes up approximately 10% of all breast cancers. The bidirectional crosstalk between HER2 and estrogen receptor (ER) in HER2+/ER+ breast cancer contributes to resistance towards both anti-estrogens and HER2-targeted therapies. TFF3 promotes breast cancer progression and has been implicated in anti-estrogen resistance in breast cancer....

Journal: :Molecular cancer therapeutics 2016
Michihiro Ishida Shunsuke Kagawa Kyoko Shimoyama Kiyoto Takehara Kazuhiro Noma Shunsuke Tanabe Yasuhiro Shirakawa Hiroshi Tazawa Hisataka Kobayashi Toshiyoshi Fujiwara

Peritoneal dissemination is the most frequent metastasis in gastric cancer and is associated with poor prognosis. The lack of particular target antigens in gastric cancer other than HER2 has hampered the development of treatments for peritoneal dissemination of gastric cancer. We hypothesized that HER2-extracellular domain (HER2-ECD) gene transduction combined with trastuzumab-based photoimmuno...

Journal: :Molecular cancer research : MCR 2013
Kaushal Asrani Ruth A Keri Rebeca Galisteo Sharron A N Brown Sarah J Morgan Arundhati Ghosh Nhan L Tran Jeffrey A Winkles

HER2 overexpression occurs in 15% to 20% of all breast cancers and is associated with increased metastatic potential and poor patient survival. Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2-HER3 heterodimers and drives breast cancer cell growth and metastasis. In a previous study, we found that fibroblast growt...

2013
GIL BAR-SELA DOV HERSHKOVITZ NISSIM HAIM ORIT KAIDAR-PERSON KATERINA SHULMAN OFER BEN-IZHAK

Human epidermal growth factor 2 (HER2) positivity rates for gastric or gastroesophageal junction (GEJ) adenocarcinoma have been reported at 15-25%. Cyclin D1 (BCL1) is a non-specific proliferative marker. The prognostic significance of HER2 and cyclin D1 is inconclusive, with contradictory data. The aim of this study was to evaluate the incidence of HER2 overexpression in gastric or GEJ patient...

Journal: :ESMO open 2023

The antibody-drug conjugate (ADC) trastuzumab deruxtecan is not only efficient in HER2 amplified breast cancers (BC), but also BC with lower protein expression levels of HER2. These low tumors are well described for non-special type BC, data on ILC lacking. Here, we aim at reporting the prevalence and analyzing its association clinicopathological features survival patients early pure estrogen r...

Journal: :Cancer research 2011
Ritwik Ghosh Archana Narasanna Shizhen Emily Wang Shuying Liu Anindita Chakrabarty Justin M Balko Ana María González-Angulo Gordon B Mills Elicia Penuel John Winslow Jeff Sperinde Rajiv Dua Sailaja Pidaparthi Ali Mukherjee Kim Leitzel Wolfgang J Kostler Allan Lipton Michael Bates Carlos L Arteaga

In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cell surface as monomers, homodimers, and heterodimers with EGFR/HER3. The therapeutic antibody trastuzumab, an approved therapy for HER2(+) breast cancer, cannot block ligand-induced HER2 heterodimers, suggesting it cannot effectively inhibit HER2 signaling. Hence, HER2 oligomeric states may predict the odds of a ...

2017
Sayyed Nilofar Danishmalik Si-Hyeong Lee Jeong-Im Sin

In the CT26/HER2 and 4T1.2/HER2 tumor models, CT26/HER2 cells form tumors that continue to grow, whereas 4T1.2/HER2 cells form tumors that eventually regress. Here, we investigated the differences in the behaviors of these two cell lines. When immune cells from 4T1.2/HER2 tumor-bearing animals were stimulated with HER2 class I peptides, they displayed a 2-fold increase in IFN-γ levels, in respo...

Journal: :International journal of molecular medicine 2007
Anna Orlova Thuy Tran Charles Widström Torun Engfeldt Amelie Eriksson Karlström Vladimir Tolmachev

Imaging of expression of human epidermal growth factor receptor type 2 (HER2) in breast carcinomas may help to select patients eligible for trastuzumab therapy. The Affibody molecule Z(HER2:342) is a small (7-kDa) non-immunoglobulin affinity protein, which binds to HER2 with a picomolar affinity. Previously, a benzyl-DTPA conjugate of Z(HER2:342) was labeled with 111In and demonstrated good tar...

Journal: :iranian journal of basic medical sciences 0
seyedeh alia moosavian biotechnology research center, nanotechnology research center, school of pharmacy, mashhad university of medical sciences, mashhad, iran mahmoud reza jaafari biotechnology research center, nanotechnology research center, school of pharmacy, mashhad university of medical sciences, mashhad, iran seyed mohammad taghdisi targeted drug delivery research center, school of pharmacy, mashhad university of medical sciences, mashhad, iran fatemeh mosaffa biotechnology research center, pharmacy school, mashhad university of medical sciences, mashhad, iran ali badiee nanotechnology research center, school of pharmacy, mashhad university of medical sciences, mashhad, iran khalil abnous pharmaceutical research center, school of pharmacy, mashhad university of medical sciences, mashhad, iran

objective(s): development of molecules that specifically recognize cancer cells is one of the major areas in cancer research. human epidermal growth factor receptor 2 (her2) is specifically expressed on the surface of breast cancer cells. her2 is associated with an aggressive phenotype and poor prognosis. in this study we aimed to isolate rna aptamers that specifically bind to her2 overexpressi...

2016
Jing Hou Zhirui Zhou Xingxing Chen Ruping Zhao Zhaozhi Yang Na Wei Qing Ni Yan Feng Xiaoli Yu Jinli Ma Xiaomao Guo

Growing evidence has demonstrated that human epidermal growth factor receptor 2 (HER2) is involved in the radiation response to breast cancer. However, the underlying mechanism remains elusive. Therefore, we investigated if HER2 overexpression is associated with radiosensitivity of breast cancer. We constructed breast cancer cell lines differing in HER2 expression by transducing HER2 cDNA or sh...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید